A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the absorption and elimination of different oral formulations from the healthy person's body.

Key facts

Study ID

NCT06733688

Run by

Merck Sharp & Dohme LLC

People needed

36

Starts

2022-03-23

Expected to finish

2022-04-15

Last updated by the study team

2024-12-13

Who can join

Age: 19 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Has a body mass index (BMI) ≥18.5 and ≤34 kg/m\^2, inclusive

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of clinically significant cancer (malignancy)

Where it is running

• Celerion (Site 0001) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.